Diabetes Mellitus Type 2

Merck confirms diabetes retreat

Merck confirms diabetes retreat

By Kirsty Barnes

Merck Serono intends to forge ahead with severing its investment in
diabetes and either sell or partner out its existing research and
development (R&D) activities in this field, which it no longer
feels able to compete in effectively.

Three hits for Novartis

Three hits for Novartis

By Anna Lewcock

Thursday was a good day for Novartis as EU regulators issued
positive opinions on no less than three of the company's drug
products, for the treatment of Alzheimer's, osteoporosis and Type
II diabetes.


Follow us


View more


Featured Suppliers